Advances in Drug Therapy for Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disease that mainly causes dementia. It is a serious threat to the health of the global elderly population. Considerable money and effort has been invested in the development of drug therapy for AD worldwide. Many drug therapies are currently under development or in clinical trials, based on two known mechanisms of AD, namely, Aβ toxicity and the abnormal Tau hyperphosphorylation. Numerous drugs are also being developed for other AD associated mechanisms such as neuroinflammation, neurotransmitter imbalance, oxidative damage and mitochondrial dysfunction, neuron loss and degeneration. Even so, the number of drugs that can successfully improve symptoms or delay the progression of the disease remains very limited. However, multi-drug combinations may provide a new avenue for drug therapy for AD. In addition, early diagnosis of AD and timely initiation of treatment may allow drugs that act on the early pathological processes of AD to help improve the symptoms and prevent the progression of the condition.

Keywords

Alzheimer’s disease / Aβ / tau / drug therapy

References

[1] WenkGL. Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry, 2003, 64(Suppl 9): 7-10

[2] LaneCA, HardyJ, SchottJM. Alzheimer’s disease. Eur J Neurol, 2018, 25(1): 59-70

[3] HowardR, McShaneR, LindesayJ, et al.. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med, 2012, 366(10): 893-903

[4] HydeC, PetersJ, BondM, et al.. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age Ageing, 2013, 42(1): 14-20

[5] CummingsJ, LeeG, RitterA, et al.. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y), 2020, 6(1): e12050

[6] PorteliusE, DeanRA, GustavssonMK, et al.. A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease. Alzheimers Res Ther, 2010, 2(2): 7

[7] YounkinSG. The role of Aβ42 in Alzheimer’s disease. J Physiol Paris, 1998, 92(3–4): 289-292

[8] HardyJA, HigginsGA. Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992, 256(5054): 184-186

[9] YanR, VassarR. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol, 2014, 13(3): 319-329

[10] Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci, 2020,27(1), DOI:https://doi.org/10.1186/s12929-019-0609-7

[11] NeumannU, UferM, JacobsonLH, et al.. The BACE-1 inhibitor CNP 520 for prevention trials in Alzheimer’s disease. EMBO Mol Med, 2018, 10(11): e9316

[12] ShiX-P, TugushevaK, BruceJE, et al.. β-Secretase cleavage at amino acid residue 34 in the amyloid β peptide is dependent upon γ-secretase activity. J Biol Chem, 2003, 278(23): 21286-21294

[13] SunX, HeG, SongW. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome. FASEB J, 2006, 20(9): 1369-1376

[14] FluhrerR, CapellA, WestmeyerG, et al.. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem, 2002, 81(5): 1011-1020

[15] Abdul-HaySO, SaharaT, McBrideM, et al.. Identification of BACE2 as an avid ß-amyloid-degrading protease. Mol. Neurodegene, 2012, 7(1): 1-12

[16] Alic I, Goh PA, Murray A, et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain. Mol Psychiatry, 2020, DOI:https://doi.org/10.1038/s41380-020-0806-5

[17] KumarD, GaneshpurkarA, KumarD, et al.. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead. Eur J Med Chem, 2018, 148: 436-452

[18] HenleyDB, MayPC, DeanRA, et al.. Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin Pharmacother, 2009, 10(10): 1657-1664

[19] DoodyRS, RamanR, FarlowM, et al.. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med, 2013, 369(4): 341-350

[20] CoricV, SallowayS, van DyckCH, et al.. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol, 2015, 72(11): 1324-1333

[21] PostinaR. A closer look at α-secretase. Curr Alzheimer Res, 2008, 5(2): 179-186

[22] MarcadeM, BourdinJ, LoiseauN, et al.. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. J Neurochem, 2008, 106(1): 392-404

[23] LahiriDK, ChenD, MaloneyB, et al.. The experimental Alzheimer’s disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice. J Pharmacol Exp Ther, 2007, 320(1): 386-396

[24] TeichAF, SharmaE, BarnwellE, et al.. Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimers Dement (N Y), 2018, 4(1): 37-45

[25] CummingsJ, LeeG, RitterA, et al.. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y), 2019, 5: 272-293

[26] WangJ, GuBJ, MastersCL, et al.. A systemic view of Alzheimer disease—insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol, 2017, 13(10): 612

[27] MawuenyegaKG, SigurdsonW, OvodV, et al.. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science, 2010, 330(6012): 1774-1774

[28] SevignyJ, ChiaoP, BussièreT, et al.. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 2016, 537(7618): 50-56

[29] SelkoeDJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol, 2019, 15(7): 365-366

[30] HungSY, FuWM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci, 2017, 24(1): 47

[31] VandenbergheR, RinneJO, BoadaM, et al.. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer’s Res Ther, 2016, 8(1): 18

[32] PanzaF, SolfrizziV, ImbimboBP, et al.. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?. Expert Opin Biol Ther, 2014, 14(10): 1465-1476

[33] OstrowitzkiS, LasserRA, DorflingerE, et al.. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer’s Res Ther, 2017, 9(1): 95

[34] TariotPN, LoperaF, LangbaumJB, et al.. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y), 2018, 4: 150-160

[35] BoadaM, LópezO, NúñezL, et al.. Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Alzheimers Dement (N Y), 2019, 5: 61-69

[36] WiessnerC, WiederholdKH, TissotAC, et al.. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci, 2011, 31(25): 9323-9331

[37] WangCY, WangPN, ChiuMJ, et al.. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimers Dement (N Y), 2017, 3(2): 262-272

[38] DodelR, DuY, DepboyluC, et al.. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 2004, 75(10): 1472-1474

[39] DodelR, NeffF, NoelkerC, et al.. Intravenous immunoglobulins as a treatment for Alzheimer’s disease. Drugs, 2010, 70(5): 513-528

[40] DodelR, RomingerA, BlennowK, et al.. P4–411: A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer’s disease (GAM10-04). Alzheimers Dement, 2011, 7: e55-e56

[41] KadavathH, HofeleRV, BiernatJ, et al.. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci, 2015, 112(24): 7501-7506

[42] WangJZ, TianQ. Mechanisms of Tau hyperphosphorylation and its role in neuronal degeneration in Alzheimer’s disease (In Chinese). Adv Biochem Biophysics, 2012, 39(8): 771-777

[43] AlonsoA, Grundke-IqbalI, IqbalK. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med, 1996, 2(7): 783-787

[44] FeinsteinSC, WilsonL. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta Mol Basis Dis, 2005, 1739(2–3): 268-279

[45] WangJZ, XiaYY, Grundke-IqbalI, et al.. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis, 2013, 33(Suppl 1): S123-S139

[46] SerenoL, ComaM, RodriguezM, et al.. A novel GSK-3β inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis, 2009, 35(3): 359-367

[47] ZhangX, HengX, LiT, et al.. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimers Dis, 2011, 24(4): 739-749

[48] MorrisG, BerkM. The putative use of lithium in Alzheimer’s disease. Curr Alzheimer Res, 2016, 13(8): 853-861

[49] van EerselJ, KeYD, LiuX, et al.. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models. Proc Natl Acad Sci USA, 2010, 107(31): 13888-13893

[50] MalpasCB, VivashL, GencS, et al.. A phase IIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate Alzheimer’s disease. J Alzheimers Dis, 2016, 54(1): 223-232

[51] ChohanMO, KhatoonS, IqbalIG, et al.. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett, 2006, 580(16): 3973-3979

[52] IqbalK, ZaidiT, WenG, et al.. Defective brain microtubule assembly in Alzheimer’s disease. Lancet, 1986, 328(8504): 421-426

[53] DefensorE, FarmerG, GanL, et al.. Effects of TPI 287, a novel taxoid, on a transgenic mouse model of Alzheimer’s disease. Neuroscience Meeting Planner, 2014, Washington, DC, Society for NeuroscienceOnline

[54] TsaiRM, MillerZ, KoestlerM, et al.. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol, 2020, 77(2): 215-224

[55] PabanV, ManriqueC, FilaliM, et al.. Therapeutic and preventive effects of methylene blue on Alzheimer’s disease pathology in a transgenic mouse model. Neuropharmacology, 2014, 76: 68-79

[56] PedersenJT, SigurdssonEM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med, 2015, 21(6): 394-402

[57] TheunisC, Crespo-BielN, GafnerV, et al.. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One, 2013, 8(8): e72301

[58] YiannopoulouKG, PapageorgiouSG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis, 2020, 12: 1179573520907397

[59] RogersJ, WebsterS, LueLF, et al.. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging, 1996, 17(5): 681-686

[60] HeppnerFL, RansohoffRM, BecherB. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci, 2015, 16(6): 358-372

[61] HolmesC, CunninghamC, ZotovaE, et al.. Systemic inflammation and disease progression in Alzheimer disease. Neurology, 2009, 73(10): 768-774

[62] ZhangC, GriciucA, HudryE, et al.. Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci Rep, 2018, 8(1): 1-9

[63] DominySS, LynchC, ErminiF, et al.. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv, 2019, 5(1): eaau3333

[64] Detke M, Lynch C, Holsinger L, et al. COR388 for the Treatment of Alzheimer’s Disease (4098). In: AAN Enterprises, 2020

[65] WangX, SunG, FengT, et al.. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res, 2019, 29(10): 787-803

[66] HampelH, MesulamMM, CuelloAC, et al.. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 2018, 141(7): 1917-1933

[67] WangR, ReddyPH. Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis, 2017, 57(4): 1041-1048

[68] ZádoriD, VeresG, SzalárdyL, et al.. Alzheimer’s disease: recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines. J Alzheimers Dis, 2018, 62(2): 523-547

[69] HardyJ, AdolfssonR, AlafuzoffI, et al.. Transmitter deficits in Alzheimer’s disease. Neurochem Int, 1985, 7(4): 545-563

[70] MatsunagaS, KishiT, IwataN. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PloS One, 2015, 10(4): e0123289

[71] WangX, WangW, LiL, et al.. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis, 2014, 1842(8): 1240-1247

[72] OkenBS, StorzbachDM, KayeJA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol, 1998, 55(11): 1409-1415

[73] VellasB, ColeyN, OussetPJ, et al.. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol, 2012, 11(10): 851-859

[74] KimuraT, HayashidaH, MurataM, et al.. Effect of ferulic acid and Angelica archangelica extract on behavioral and psychological symptoms of dementia in frontotemporal lobar degeneration and dementia with Lewy bodies. Geriatr Gerontol Int, 2011, 11(3): 309-314

[75] Kudoh C, Hori T, Yasaki S, et al. Effects of Ferulic Acid and Angelica archangelica Extract (Feru-guard®) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial. J Alzheimers Dis Rep, 2020(Preprint):1–6

[76] MatsuyamaK, YamamotoY, SoraI. Effect of Feruguard 100M on amyloid-beta deposition in individuals with mild cognitive impairment. Psychogeriatrics, 2020, 20(5): 726-736

[77] KabirM, UddinM, MamunAA, et al.. Combination drug therapy for the management of Alzheimer’s disease. Int J Mol Med Sci, 2020, 21(9): 3272